Cyient DLM Q2 FY27 : Strategic Investments

Executive SummaryCyient DLM reported a mixed second quarter, characterized by robust top-line expansion and an unprecedented order pipeline, counterbalanced by near-term margin compression. While the market reacted negatively to the margin contraction, management's retention of long-term guidance suggests the foundational growth thesis remains intact. Financial & Operational HighlightsRevenue Growth: Revenue surged 26.5% year-over-year to ₹393.1 crore, predominantly driven by sustained momentum in the aerospace and industrial verticals. Margin Contraction: EBITDA margins compressed by 130 basis points YoY to 8.7%, while gross margins contracted by 400 bps to 37.4%. Management attributed this compression to front-loaded, strategic investments in sales, marketing, and R&D, which are now largely concluded. Profitability: Normalized net profit grew 25.8% YoY, while the reported PAT includes a one-time earnout reversal gain of ₹18.2 crore. Order Book & Capital Efficiency: The order book achieved an all-time high of ₹2,813.7 crore (a 23% YoY increase), providing strong revenue visibility for the next 18 to 24 months. However, net working capital days expanded from 138 to 154 days. Forward Outlook & Market ReactionManagement reaffirmed its FY27 guidance, projecting 30–35% revenue growth with EBITDA margins stabilizing between 8–9%. Leadership is explicitly targeting a return to double-digit margins by FY28 and a long-term margin framework of 13–18% by FY30. In response to the margin profile, the stock experienced a sharp 17% pullback on October 16, though it remains up over 100% year-to-date. Analyst sentiment currently reflects near-term caution, with Antique Stock Broking downgrading the stock to "Hold" (Target: ₹1,025) and Kotak maintaining a "Sell" rating (Target: ₹790).